Quality of life in institutionalized patients with schizophrenia

• Authors: Aleksandra Petrovic Kitic , Slobodan Jankovic

Title variants

PL

Jakość życia chorych na schizofrenię przebywających w placówkach psychiatrycznych stałego pobytu

• Languages of publication: EN

Abstracts

EN

Aim: Research into quality of life has become very important recently, since quality of life is increasingly used to characterise diseases and estimate the efficiency of therapeutics. The aim of this study was to determine significant factors that are associated with the quality of life of patients with schizophrenia accommodated in social welfare institutions. Material and methods: The study was conducted at the Institution for the Accommodation of Adults “Male Pcelice,” Kragujevac, Serbia. It was designed as a cross-sectional study. The quality of life was measured by using five distinct scales. The data on factors that might be associated with the quality of life were obtained from case records and the patients’ questionnaires. The association of every single factor was evaluated by using comparative analysis and the method of multiple linear regression. Results: Multiple linear regression shows that EuroQoL Five-dimensions – Five-Level scale score was associated with gender (B = −0.059 ± 0.021; p = 0.006) and daily dose (B = −0.051 ± 0.015; p = 0.001); Quality of Life Enjoyment and Satisfaction Questionnaire score was associated with the patient’s level of education (B = 2.873 ± 1.054; р = 0.007); the number of prescribed antipsychotics was associated with the Brief Psychiatric Rating Scale score (B = 3.150 ± 1.111; р = 0.007); the physical domain of the World Health Organization Quality of Life-BREF was associated with the year of disease onset (B = −0.142 ± 0.055; р = 0.011) and the daily dose (B = −2.335 ± 0.787; р = 0.004); the psychological domain of the World Health Organization Quality of Life-BREF was associated with gender (B = −2.686 ± 1.216; р = 0.029); the social relationship domain of the World Health Organization Quality of Life-BREF was associated with the level of education (B = 3.109 ± 1.289; р = 0.017) and the number of prescribed antipsychotics (B = −3.297 ± 1.516; р = 0.031); the environment domain of the World Health Organization Quality of Life-BREF was associated with the number of prescribed antipsychotics (B = −1.420 ± 0.653; р = 0,031). Conclusion: The quality of life of patients with schizophrenia was higher in males with a university degree, when the duration of the disease was shorter, negative symptoms were less pronounced, and with fewer side effects. Efforts to improve the quality of life in patients with schizophrenia accommodated in social welfare institutions should be made that could contribute to the prevention of adverse outcomes.

PL

Cel pracy: Badania nad jakością życia nabrały ostatnio szczególnej wagi – coraz częściej kategoria ta jest stosowana do opisu chorób oraz oceny skuteczności leczenia. Celem badania była określenie istotnych czynników związanych z jakością życia pacjentów chorych na schizofrenię przebywających w placówkach psychiatrycznych stałego pobytu. Materiał i metoda: Badanie o charakterze przekrojowym zostało przeprowadzone wśród pacjentów Centrum Pobytu dla Osób Dorosłych „Male Pcelice” w miejscowości Kragujevac w Serbii. Jakość życia chorych na schizofrenię zmierzono za pomocą pięciu skal. Dane dotyczące czynników, które mogły mieć wpływ na jakość życia badanych, zostały pozyskane z dokumentacji medycznej pacjentów oraz z wypełnianych przez nich ankiet. W ocenie zależności pomiędzy jakością życia pacjentów a poszczególnymi czynnikami wykorzystano analizę porównawczą oraz metodę regresji wielorakiej. Wyniki: Metodą regresji wielorakiej wykazano, iż wynik skali EuroQoL Five-dimensions – Five-Level korelował z płcią pacjentów (B = −0,059 ± 0,021; p = 0,006) oraz dzienną dawką przyjmowanych leków (B = −0,051 ± 0,015; p = 0,001), wynik Quality of Life Enjoyment and Satisfaction Questionnaire – z poziomem wykształcenia (B = 2,873 ± 1,054; р = 0,007), liczba przyjmowanych leków przeciwpsychotycznych – z wynikiem skali Brief Psychiatric Rating Scale (B = 3,150 ± 1,111; р = 0,007), domena fizyczna skali World Health Organization Quality of Life-BREF – z czasem trwania choroby (rokiem wystąpienia choroby) (B = −0,142 ± 0,055; р = 0,011) oraz dzienną dawką przyjmowanych leków (B = −2,335 ± 0,787; р = 0,004), domena psychologiczna skali World Health Organization Quality of Life-BREF – z płcią (B = −2,686 ± 1,216; р = 0,029), domena społeczna skali World Health Organization Quality of Life-BREF – z poziomem wykształcenia (B = 3,109 ± 1,289; р = 0,017) oraz liczbą przyjmowanych leków przeciwpsychotycznych (B = −3,297 ± 1,516; р = 0,031), zaś domena środowiskowa skali World Health Organization Quality of Life-BREF – z liczbą przyjmowanych leków przeciwpsychotycznych (B = −1,420 ± 0,653; р = 0,031). Wnioski: Jakość życia chorych na schizofrenię objętych badaniem była wyższa u pacjentów płci męskiej z wyższym wykształceniem, o krótszym przebiegu choroby, z mniej dotkliwymi objawami oraz mniejszą liczbą skutków ubocznych. Poprawa jakości życia osób chorujących na schizofrenię przebywających w placówkach psychiatrycznych stałego pobytu pozwoli zapobiec niepomyślnym wynikom leczenia psychiatrycznego.

Keywords

EN

antipsychotics; quality of life; questionnaires; schizophrenia; side effects

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Psychiatria i Psychologia Kliniczna
• Year: 2018
• Volume: 18
• Issue: 1
• Pages: 5–11

Contributors

author

Aleksandra Petrovic Kitic

• Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia Institution where the study was conducted: Institution for the Accommodation of Adults “Male Pcelice,” Kragujevac, Serbia

author

Slobodan Jankovic

• Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia Institution where the study was conducted: Institution for the Accommodation of Adults “Male Pcelice,” Kragujevac, Serbia

References

• Andersen J, Larsen JK, Schultz V et al.: The Brief Psychiatric Rating Scale. Dimension of schizophrenia – reliability and construct validity. Psychopathology 1989; 22: 168–176.
• de Araújo AA, de Araújo Dantas D, do Nascimento GG et al.: Quality of life in patients with schizophrenia: the impact of socio-economic factors and adverse effects of atypical antipsychotics drugs. Psychiatr Q 2014; 85: 357–367.
• Awad AG, Voruganti LN: Measuring quality of life in patients with schizophrenia: an update. Pharmacoeconomics 2012; 30: 183–195.
• Bobes J, Garcia-Portilla MP, Bascaran MT et al.: Quality of life in schizophrenic patients. Dialogues Clin Neurosci 2007; 9: 215–226.
• Endicott J, Nee J, Harrison W et al.: Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29: 321–326.
• Gureje O, Miles W, Keks N et al.: Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res 2003; 61: 303–314.
• Ilickovic IM, Jankovic SM, Tomcuk A et al.: Pharmaceutical care in a longstay psychiatric hospital. Eur J Hosp Pharm 2016; 23: 177–181.
• Jankovic SM, Kovacevic Z, Jankovic SV et al.: Antipsychotic drug prescription in a Serbian long-stay psychiatric care facility. Clin Drug Investig 2001; 21: 679–684.
• Levine J, Chengappa KN, Patel A et al.: Obesity and medical illnesses in psychiatric patients admitted to a long-term psychiatric facility. J Psychiatr Pract 2001; 7: 432–439.
• Lingjærde O, Ahlfors UG, Bech P et al.: The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1–100.
• Lyketsos CG, Gonzales-Salvador T, Chin JJ et al.: A follow-up study of change in quality of life among persons with dementia residing in a long-term care facility. Int J Geriatr Psychiatry 2003; 18: 275–281.
• Montes JM, Ciudad A, Gascón J et al.; EFESO Study Group: Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 667–674.
• Prieto L, Sacristán JA, Hormaechea JA et al.: Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin 2004; 20: 827–835.
• Revicki DA, Genduso LA, Hamilton SH et al.: Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res 1999; 8: 417–426.
• Ritchie CW, Chiu E, Harrigan S et al.: The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psychiatry 2003; 18: 432–440.
• Ritsner M, Gibel A, Perelroyzen G et al.: Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol 2004; 24: 582–591.
• Shoja Shafti S, Gilanipoor M: A comparative study between olanzapine and risperidone in the management of schizophrenia. Schizophr Res Treatment 2014; 2014: 307202.
• Theodore K, Johnson S, Chalmers-Brown A et al.: Quality of life and illness beliefs in individuals with early psychosis. Soc Psychiatry Psychiatr Epidemiol 2012; 47: 545–551.
• The WHOQOL Group: The World Health Organization quality of life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 1995; 41: 1403–1409.
• Whynes DK; TOMBOLA Group: Correspondence between EQ-5D health state classifications and EQ VAS scores. Health Qual Life Outcomes 2008; 6: 94.
• Wilkinson G, Hesdon B, Wild D et al.: Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry 2000; 177: 42–46.

• Document Type: article